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Background: Adjuvant! Online (AOL) and Nottingham Prognostic Index (NPI) are
prognostic tools that are widely used to aid treatment decision-making. Although
performing globally well, their performance is unclear in populations other than those
used in their validation studies and particularly in specific subgroups such as
women ≤ 40 years. The present study aimed to evaluate for the first time the prognostic
performance of AOL and NPI in young early breast cancer patients.
Methods: This is a multicentre hospital-based retrospective cohort study including
young (≤ 40 years) and older (55-60 years) breast cancer patients treated from January
2000 until December 2004 at 4 large Belgian and Italian institutions. Predicted 10-year
overall survival (OS) and disease-free survival (DFS) using AOL and 10-year OS using
NPI were calculated for every patient. To assess calibration, the trimmed mean of the
predicted 10-year outcomes was compared to the observed (Kaplan-Meier estimate at
10 years) 10-year rates by using one-sample t-test. Discriminatory accuracy was
assessed by calculating the area under the receiver-operator characteristic curve and the
corresponding 95% confidence intervals for 10-year predicted OS and DFS. Vital status
was cross-checked with the national registries in Belgium and Italy.
Results: A total of 1,283 patients were included (376 in the young and 907 in the older
cohorts, respectively). AOL accurately predicted 10-year OS (absolute difference: 0.66%;
p = 0.37) in the young cohort, but overestimated 10-year DFS by 7.66% (p = 0.003). In
the older cohort, AOL significantly underestimated both 10-year OS and DFS, by 7.20%
(p < 0.001) and 3.12% (p = 0.04), respectively. NPI significantly underestimated 10-year
OS in both the young (8.46%; p < 0.001) and the older (4.04%; p < 0.001) cohorts. AOL
and NPI had comparable discriminatory accuracy in predicting both OS and DFS.
Conclusions: In young breast cancer patients, AOL is a reliable tool in predicting OS at
10 years but not DFS, while the calibration performance of NPI is suboptimal. In
patients aged 55-60 years, the role of AOL and NPI deserves further investigations.
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